◼ Archived
Business
Seven new tumor cases reported among patients on Novartis’ Zolgensma gene therapy
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Sma
3 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
Novartis reports cases of tumors in children following treatment with its spinal muscular atrophy gene therapy, Zolgensma.
◼ Archived
Business
Roche Halts Development of Obesity Drug Candidate
Roche has halted the development of emugrobart, a muscle-preserving obesity drug candidate, following a failed interim analysis.